Document is current
Any future updates will be listed below
-
Authors
Lo, Wan-Lin http://orcid.org/0000-0002-9074-6847
Kuhlmann, Miriam http://orcid.org/0000-0001-7431-9637
Rizzuto, Gabrielle http://orcid.org/0000-0003-3052-0253
Ekiz, H. Atakan
Kolawole, Elizabeth M. http://orcid.org/0000-0003-3138-0037
Revelo, Monica P.
Andargachew, Rakieb
Li, Zhongmei
Tsai, Yuan-Li
Marson, Alexander http://orcid.org/0000-0002-2734-5776
Evavold, Brian D.
Zehn, Dietmar http://orcid.org/0000-0003-1393-8527
Weiss, Arthur http://orcid.org/0000-0002-2414-9024
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI143960, AI137209, AI147641, AI167422, AI091580)
U of U | School of Medicine
Memorial Sloan-Kettering Cancer Center
Türkiye Bilimsel ve Teknolojik Araştirma Kurumu (TUBITAK-2232b 121C115)
Cancer Research Institute (Lloyd J. Old STAR award)
Parker Foundation
Deutsche Forschungsgemeinschaft (SFB1054, SFB1371)
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 1 September 2022
Accepted: 25 January 2023
First Online: 13 March 2023
Competing interests
: A.M. is a cofounder of Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics. A.M. serves on the board of directors at Spotlight Therapeutics and Survey Genomics and is board observer at Arsenal Biosciences. A.M. is a member of the scientific advisory boards of Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics and NewLimit. A.M. owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma and Merck. A.M. has received fees from Arsenal Biosciences, Spotlight Therapeutics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein and Analytical, Life Science & Diagnostics Association (ALDA). A.M. is an investor in and informal adviser to Offline Ventures and a client of EPIQ Capital Group. The A.M. laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem. D.Z. has a consulting agreement and research collaboration agreement with Pieris Pharmaceuticals. A.W. is a cofounder and consultant of Nurix Therapeutics. A.W. is on the scientific advisory boards at BlueSphere Bio, BridGene Biosciences, Genentech, Jasper Therapeutics and Soteria Biotherapeutics. He receives consulting fees and has received stock options or owns stock in these companies. The other authors declare no competing interests.
